Infu System Holdings, Inc INFU
We take great care to ensure that the data presented and summarized in this overview for InfuSystem Holdings, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INFU
View all-
Awm Investment Company, Inc. New York, NY1.9MShares$16.8 Million1.74% of portfolio
-
Black Rock Inc. New York, NY1.24MShares$11 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.12MShares$9.93 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN960KShares$8.5 Million0.38% of portfolio
-
Minerva Advisors LLC Bala Cynwyd, PA847KShares$7.5 Million3.8% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX771KShares$6.83 Million0.34% of portfolio
-
First Eagle Investment Management, LLC722KShares$6.39 Million0.01% of portfolio
-
Harbert Fund Advisors, Inc. Birmingham, AL618KShares$5.48 Million2.45% of portfolio
-
Meros Investment Management, LP Dallas, TX615KShares$5.45 Million1.91% of portfolio
-
Heartland Advisors Inc Milwaukee, WI500KShares$4.43 Million0.18% of portfolio
Latest Institutional Activity in INFU
Top Purchases
Top Sells
About INFU
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Insider Transactions at INFU
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
Scott Shuda Director |
SELL
Other acquisition or disposition
|
Indirect |
42,241
-12.4%
|
-
|
|
Nov 27
2024
|
Richard Dilorio Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,398
-1.28%
|
$43,184
$8.87 P/Share
|
|
Nov 26
2024
|
Richard Dilorio Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,602
-3.34%
|
$116,816
$8.91 P/Share
|
|
Nov 25
2024
|
Richard Dilorio Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-4.38%
|
$180,000
$9.32 P/Share
|
|
Oct 31
2024
|
Addam Chupa Executive VP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,720
-18.99%
|
$52,320
$6.19 P/Share
|
|
Oct 31
2024
|
Addam Chupa Executive VP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.34%
|
-
|
|
Oct 09
2024
|
Jerod Funke EVP-Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-27.18%
|
$22,014
$6.77 P/Share
|
|
Oct 09
2024
|
Jerod Funke EVP-Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+48.08%
|
-
|
|
Sep 23
2024
|
Kenneth D. Eichenbaum Director |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$20,000
$5.89 P/Share
|
|
Jun 26
2024
|
Richard Dilorio Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,347
-7.01%
|
$206,082
$6.83 P/Share
|
|
Jun 26
2024
|
Richard Dilorio Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+9.26%
|
$100,000
$2.69 P/Share
|
|
May 23
2024
|
Ralph F Boyd Jr Director |
BUY
Open market or private purchase
|
Direct |
4,000
+40.0%
|
$28,000
$7.13 P/Share
|
|
May 22
2024
|
Beverly A Huss Director |
BUY
Open market or private purchase
|
Direct |
4,300
+50.0%
|
$25,800
$6.86 P/Share
|
|
May 21
2024
|
Addam Chupa Executive VP and CIO |
BUY
Open market or private purchase
|
Direct |
1,000
+3.88%
|
$6,000
$6.67 P/Share
|
|
May 20
2024
|
Barry G Steele Executive VP and CFO |
BUY
Open market or private purchase
|
Direct |
3,000
+4.1%
|
$18,000
$6.47 P/Share
|
|
May 20
2024
|
Jerod Funke EVP-Chief HR Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$6,000
$6.39 P/Share
|
|
May 20
2024
|
Paul Andrew Gendron Director |
BUY
Open market or private purchase
|
Direct |
5,000
+7.14%
|
$30,000
$6.54 P/Share
|
|
May 18
2024
|
Carrie Lachance President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,179
-1.7%
|
$19,074
$6.44 P/Share
|
|
May 18
2024
|
Carrie Lachance President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,077
+4.15%
|
-
|
|
May 18
2024
|
Richard Dilorio Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,819
-1.53%
|
$40,914
$6.44 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 23.4K shares |
|---|---|
| Exercise of conversion of derivative security | 200K shares |
| Open market or private purchase | 22.3K shares |
| Payment of exercise price or tax liability | 115K shares |
|---|---|
| Open market or private sale | 40K shares |
| Other acquisition or disposition | 42.2K shares |